Related Experiment Video
Updated: Aug 23, 2025

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Management of Axial Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021
Ennio Lubrano1, Jon Chan2, Ruben Queiro-Silva3
1E. Lubrano, MD, PhD, Academic Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy; enniolubrano@hotmail.com.
Objective:
Axial involvement in patients with psoriatic arthritis (PsA) is a common subset of this condition, but a unanimous definition has yet to be established. It has been defined by using different criteria, ranging from the presence of at least unilateral grade 2 sacroiliitis to those used for ankylosing spondylitis (AS), or simply the presence of inflammatory low back pain (IBP). Our aim was to identify and evaluate the efficacy of therapeutic interventions for treatment of axial disease in PsA.
Methods:
This systematic review is an update of the axial PsA (axPsA) domain of the treatment recommendations project by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
Results:
The systematic review of the literature showed that new biologic and targeted synthetic disease-modifying antirheumatic drug classes, namely interleukin (IL)-17A and Janus kinase inhibitors, could be considered for the treatment of axPsA. This would be in addition to previously recommended treatments such as nonsteroidal antiinflammatory drugs, physiotherapy, simple analgesia, and tumor necrosis factor inhibitors. Conflicting evidence still remains regarding the use of IL-12/23 and IL-23 inhibitors.
Conclusion:
Further studies are needed for a better understanding of the treatment of axPsA, as well as validated outcome measures.
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Rheumatic Heart Disease III: Medical Management
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Atherosclerosis III: Management
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Psychosis: Goals of Pharmacotherapy

